Access to Medicines – Page 16

Europe’s Beating Cancer Plan: Let’s focus on treatments that bring the most value to patients

by European Public Health Alliance | Mar 30, 2021 | Opinion

Guest article: Lydie Meheus, Belgian AntiCancer Fund To fight cancer, Europe needs a whole-of-government approach that puts patients’ needs at the centre, driving change for the benefit of citizens and reducing the suffering caused by cancer. The Anticancer Fund...

Sustainable access to effective antibiotics – what should the EU do?

by EPHA | Mar 17, 2021

Sustainable access to effective antibiotics – what should the EU do?  15 April 2021  16:00-17:00 CET  Online How can we solve the AMR epidemic? What is the role of the EU? What can HERA do? The scientific and structural difficulties in discovering new...

Why and how should we prioritize marginalized communities in the rollout of COVID-19 vaccines in Europe?

by EPHA | Mar 9, 2021

Why and how should we prioritize marginalized communities in the rollout of COVID-19 vaccines in Europe?  25 March 2021  16:00 - 17:00 CET  Webinar Public health means protection of the population as a whole and health for all. It is not only a question of...

HERA should be independent and autonomous with a clear public health mission, EPHA says

by European Public Health Alliance | Feb 24, 2021 | Consultation Responses

EPHA’s submission to the feedback mechanism on the on the HERA (Health Emergency Preparedness and Response Authority) inception impact assessment The COVID-19 pandemic has shown that Europe has paid the price of not being prepared in the biomedical research &...

After COVID-19, what’s next for EU medicines policies?

by EPHA | Feb 15, 2021

After COVID-19, what’s next for EU medicines policies?  9 March 2021  16:00 - 17:00 CET  Online Continuing our successful online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry...